The activation of EP300 by F11R leads to EMT and acts as a prognostic factor in triple-negative breast cancers

Abstract A role for the JAM family in cancer progression has been demonstrated. Nevertheless, there has been no systematic study of the JAM family in specific cancers through clinical specimens, and the mechanism of the molecule is unclear, particularly in subtypes of breast cancer (BRCA). Based on an extensive analysis of the relative expression of the JAM family in cancer by pan-cancer, we found that the increase of F11R (JAM-A) is the opposite of that of JAM-2, or JAM-3, which is unique to BRCA. BRCA prognoses are related to F11R expression, including survival and recurrence-free survival. It is also noteworthy that F11 has different expression characteristics in subtypes, especially in triple-negative breast cancer (TNBC). Using immunohistochemistry (IHC) analysis as an analytical validation, this study provides consistent results with in-silico. As a result of artificial manipulations of F11R combined with microarray-based analyses, we identified that F11R plays an important role in several aspects of cell motility signaling. An upstream regulators and correlation analysis found that EP300 transcription factors may be involved in TNBC metastasis by modulating RHOA, GSK3B, and TGFBR1 expression through F11R-mediated epithelial-mesenchymal transition (EMT). Accordingly, the findings of this study provide a comprehensive interpretation of the relationship between the clinical value of F11R in BRCA subtype progression and the mechanisms that induce metastasis. These results provide a possible target for the treatment of BRCA.